SML3925
Liraglutide
≥95% (HPLC), GLP-1 receptor agonist, Powder or Lyophilized powder or film
别名:
Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥95% (HPLC)
Form:
(Powder or Lyophilized powder or film)
产品名称
Liraglutide, ≥95% (HPLC)
Quality Segment
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
color
white to off-white
storage temp.
-10 to -25°C
Biochem/physiol Actions
Glucagon-like peptide-1 (GLP-1)-based incretin mimetic with enhanced in vivo stability and efficacy against type 2 diabetes and obesity.
Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).
signalword
Warning
hcodes
存储类别
11 - Combustible Solids
wgk
WGK 3
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2